Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026, Pennsylvania, Allentown Beloud

@wfmz.com · 1 hour

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026

Ollin Biosciences has successfully secured $330 million in an oversubscribed Series B financing round. The funding, co-led by TCGX and ARCH Venture Partners, will support the global Phase 3 ...

Read more Wfmz.com

1 Shares